Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, P.R. China; Department of Molecular Neuropathology, Beijing Neurosurgical Institute, Capital Medical University, Beijing 100070, P.R. China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, P.R. China.
Cell Metab. 2024 Aug 6;36(8):1696-1710.e10. doi: 10.1016/j.cmet.2024.07.011.
Patients with high ALDH1A3-expressing glioblastoma (ALDH1A3 GBM) show limited benefit from postoperative chemoradiotherapy. Understanding the mechanisms underlying such resistance in these patients is crucial for the development of new treatments. Here, we show that the interaction between ALDH1A3 and PKM2 enhances the latter's tetramerization and promotes lactate accumulation in glioblastoma stem cells (GSCs). By scanning the lactylated proteome in lactate-accumulating GSCs, we show that XRCC1 undergoes lactylation at lysine 247 (K247). Lactylated XRCC1 shows a stronger affinity for importin α, allowing for greater nuclear transposition of XRCC1 and enhanced DNA repair. Through high-throughput screening of a small-molecule library, we show that D34-919 potently disrupts the ALDH1A3-PKM2 interaction, preventing the ALDH1A3-mediated enhancement of PKM2 tetramerization. In vitro and in vivo treatment with D34-919 enhanced chemoradiotherapy-induced apoptosis of GBM cells. Together, our findings show that ALDH1A3-mediated PKM2 tetramerization is a potential therapeutic target to improve the response to chemoradiotherapy in ALDH1A3 GBM.
高表达 ALDH1A3 的胶质母细胞瘤(ALDH1A3 GBM)患者术后接受放化疗获益有限。了解此类患者产生耐药的机制对于开发新的治疗方法至关重要。在这里,我们发现 ALDH1A3 与 PKM2 之间的相互作用增强了后者的四聚化,并促进了胶质瘤干细胞(GSCs)中的乳酸积累。通过扫描乳酸积累的 GSCs 中的乳酰化蛋白质组,我们发现 XRCC1 在赖氨酸 247(K247)处发生乳酰化。乳酰化的 XRCC1 对导入蛋白 α的亲和力更强,允许 XRCC1 更大程度地核易位,并增强 DNA 修复。通过对小分子文库进行高通量筛选,我们发现 D34-919 能够有效地破坏 ALDH1A3-PKM2 相互作用,从而阻止 ALDH1A3 介导的 PKM2 四聚化增强。在体外和体内,D34-919 治疗增强了放化疗诱导的 GBM 细胞凋亡。总之,我们的研究结果表明,ALDH1A3 介导的 PKM2 四聚化是提高 ALDH1A3 GBM 对放化疗反应的潜在治疗靶点。
Cell Metab. 2024-8-6
J Clin Invest. 2019-4-8
Int J Mol Sci. 2018-9-11
Biomolecules. 2021-10-21
Oncol Lett. 2025-8-20
Cancer Drug Resist. 2025-8-4
J Transl Med. 2025-8-12
Front Immunol. 2025-7-25
Front Oncol. 2025-6-25